ClinicalTrials.gg
Not yet recruitingNCT06356506Updated Apr 19, 2024

A Study on Factors of Biochemical Response in Autoimmune Hepatitis

An observational study in Autoimmune Hepatitis, sponsored by Beijing Friendship Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Beijing Friendship Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
630
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hepatitis, Autoimmune with a site in China — 3 open to participants now, 3 under way, 1 of them phase 3. Hepatitis, Autoimmune · China.

Started
2024
the only one that year
Observational
6 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
2 of 16
Beijing Friendship Hospital

Among the 16 studies in Hepatitis, Autoimmune with a site in China, this one is the only one that started in 2024, is one of 6 observational ones, and was the 14th registered.

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

Browse Hepatitis, Autoimmune studies →

Open to participants now

3 of the 16 studies in Hepatitis, Autoimmune with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Hepatitis, Autoimmune studies recruiting now, 9 (56%) set no upper age limit and 4 (25%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hepatitis, Autoimmune with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to clarify the clinical characteristics of autoimmune hepatitis (AIH) in China. The main questions it aims to answer are:

Human leukocyte antigen (HLA) gene susceptibility in Chinese AIH patients prognostic factors associated with AIH Participants will provide liver tests results and details of treatment during follow-up.

Read the detailed description

This study aims to establish a high-quality, standardized prospective cohort of AIH with regular follow-up, clarify the clinical characteristics of AIH in China, construct a prognostic model, and explore new serum markers or AIH gene susceptibility, so as to provide key clinical evidence for the prevention and treatment of AIH in China.

03

Conditions studied

  • Autoimmune Hepatitis

Browse trials for

Keywords

  • Autoimmune hepatitis
  • Biochemical response
  • Prognosis
  • Immunosuppressive therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

AIH patients who fulfilled the inclusion and exclusion criteria were enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old at the time of onset;
  2. AIH simplified score ≥6 and/or AIH revised score ≥10;
  3. Liver was performed and consistent with the pathological diagnosis of AIH;
  4. Patents were treatment naive or who were diagnosed and treated in other hospitals but have stopped / therapy for more than 3 months;
  5. Agree to participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. concomitant liver diseases: hepatotropic viral hepatitis (A, B, C, D, and E) and non-hepatotropic viral hepatitis (cytomegalovirus and Epstein-Barr virus (EBV) infection);
  2. concomitant with drug-induced liver injury, primary biliary cholangitis, primary sclerosing cholangitis, alcoholic liver disease, genetic and metabolic liver diseases;
  3. bone marrow or liver transplantation;
  4. incomplete baseline medical history and laboratory examination results;
  5. for previously diagnosed patients, therapy was discontinued less than 3 months;
  6. Pregnancy or lactation;
  7. patients with to /immunosuppressive therapy;
  8. complicated with other malignant tumors;
  9. complicated with mental disorders.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
630 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Modeling group

    The data of modeling group is used to construct a predictive model of AIH end-point events.

  • Validation group

    Validation group is used to validate the predictive model externally.

06

What researchers measure

Primary outcomes

  1. Alanine aminotransferase (ALT) recovery

    Normalization of ALT

    Time frame: From time of enrollment to the date of first ALT recovery, assessed up to 120 months

  2. Aspartate transaminase (AST) recovery

    Normalization of AST

    Time frame: From time of enrollment to the date of first AST recovery, assessed up to 120 months

  3. Immunoglobulin G (IgG) recovery

    Normalization of IgG

    Time frame: From time of enrollment to the date of first IgG recovery, assessed up to 120 months

  4. Death

    Patients die because of liver diseases

    Time frame: From time of enrollment to the date of death from liver disease, assessed up to 120 months

  5. Liver transplantaiton

    Patients have liver transplantation because of AIH

    Time frame: From time of enrollment to the date of liver transplantation, assessed up to 120 months

  6. Progression to hepatocellular carcinoma (HCC)

    Patients progress to hepatocellular carcinoma due to poor treatment response

    Time frame: From time of enrollment to the first date of HCC diagnosed, assessed up to 120 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for May 2034, 120 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Apr 10, 2024
StartEst.
May 1, 2024
Primary completionEst.
May 1, 2034
CompletionEst.
May 1, 2034
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06356506
Responsible party
Zhao Xinyan (Director, Principal Investigator, Clinical Professor, Beijing Friendship Hospital) — Principal investigator
First posted
Apr 10, 2024
Start date
May 1, 2024 (estimated)
Primary completion
May 1, 2034 (estimated)
Completion
May 1, 2034 (estimated)
Last update
Apr 19, 2024

Study contacts

Yu Su
Contact
suyu_7912@163.com
18810639513
Qianyi Wang
Contact
wangqy1001@hotmail.com
18519667363
Xinyan Zhao
study chair · Beijing Friendship Hospital
Zhengsheng Zou
study chair · Beijing 302 Hospital
Yu Chen
principal investigator · Beijing You 'an Hospital, Capital Medical University
Jia Li
principal investigator · Tianjin Second People's Hospital
Jingshou Chen
principal investigator · The First Affiliated Hospital of Xiamen University
Liang Wang
principal investigator · Lanzhou University Second Hospital
Huahua Wang
principal investigator · Jiaozuo People's Hospital
Xiaoli Hu
principal investigator · Heilongjiang Provincinal Hospital
Pingying Li
principal investigator · Qinghai People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion